Authors:
CHOUAKI N
TAAMMA A
LADEM A
DELALOGE S
MISSET JL
PAUTIER P
LHOMME C
CVITKOVIC E
Citation: N. Chouaki et al., FEASIBILITY TRIAL OF PACLITAXEL (PXL), OXALIPLATIN (L-OHP) AND CISPLATIN (CDDP) COMBINATION IN ADVANCED OVARIAN-CANCER PATIENTS, Annals of oncology, 9, 1998, pp. 346-346
Authors:
RIOFRIO M
TAAMMA A
MCKRANTER B
GOLDWASSER F
JIMENO J
JASMIN C
MISSET JL
CVITKOVIC E
Citation: M. Riofrio et al., ECTEINASCIDIN-743 (ET-743) 24 HOURS CONTINUOUS-INFUSION (CI) - CLINICAL AND PHARMACOKINETIC PHASE-I STUDY PROGRESSIVE REPORT, Annals of oncology, 9, 1998, pp. 639-639
Authors:
CVITKOVIC E
MEKRANTER B
TAAMMA A
GOLDWASSER F
BEIJNEN JH
JIMENO J
RIOFRIO M
VEGA E
MISSET JL
HOP P
Citation: E. Cvitkovic et al., ECTEINASCIDIN-743 (ET-743) 24-HOUR CONTINUOUS INTRAVENOUS-INFUSION (CI) PHASE-I STUDY IN SOLID TUMORS (ST) PATIENTS, Annals of oncology, 9, 1998, pp. 456-456
Authors:
FANDI A
TAAMMA A
AZLI N
BACHOUCHI M
YANES B
ARMAND JP
CVITKOVIC E
Citation: A. Fandi et al., PALLIATIVE TREATMENT WITH LOW-DOSE CONTINUOUS-INFUSION 5-FLUOROURACILIN RECURRENT AND OR METASTATIC UNDIFFERENTIATED NASOPHARYNGEAL CARCINOMA TYPE/, Head & neck, 19(1), 1997, pp. 41-47
Authors:
TAAMMA A
CVITKOVIC E
JIMENO J
GASPARETTO M
MEELEY K
VEGA E
CAMERON L
MISSET JL
Citation: A. Taamma et al., PHASE-I CLINICAL-STUDY OF ECTEINASCIDIN-743 (ET-743) AS A 24 HOURS CONTINUOUS INTRAVENOUS-INFUSION (CI) IN PATIENTS (PTS) WITH SOLID TUMORS(ST) - A PROGRESS REPORT, European journal of cancer, 33, 1997, pp. 1119-1119
Authors:
SOULIE P
TRANDAFIR L
TAAMMA A
LOKIEC F
BRAIN E
DELORD JP
MITA A
VANNETZEL JM
CVITKOVIC E
MISSET JL
Citation: P. Soulie et al., SCHEDULE-DEPENDENT PACLITAXEL TOLERANCE ACTIVITY - DATA FROM A 7 DAY INFUSION PHASE-I STUDY WITH PHARMACOKINETICS IN PACLITAXEL REFRACTORY OVARIAN-CANCER/, Anti-cancer drugs, 8(8), 1997, pp. 763-766
Authors:
CVITKOVIC E
ESCHWEGE F
RAHAL M",DOSEN,"MERSIC Z
KRAJINA Z
ARMAND JP
BOUHRIS J
TUBIANAMATHIEU M
FOUNTZILAS G
KOSMIDIS PA
PRASAD U
GANESAN S
ELGUEDDARI B
BACHOUCHI M
MANSOURI A
OLIVEIRA J
RAPOSO J
WIERZBICKI R
LIANES P
PENA C
ONAT H
ALTUN M
BENHAMOU E
DUCOURTIEUX M
AZLI N
FANDI A
TAAMMA A
BOSQ J
KLIJANIENKO J
SIGAL R
HONG WK
VOKES EE
CLARK JR
LEFLOCH O
BERNIER J
Citation: E. Cvitkovic et al., PRELIMINARY-RESULTS OF A RANDOMIZED TRIAL COMPARING NEOADJUVANT CHEMOTHERAPY (CISPLATIN, EPIRUBICIN, BLEOMYCIN) PLUS RADIOTHERAPY VS RADIOTHERAPY ALONE IN STAGE-IV (GREATER-THAN-OR-EQUAL-TO-N2, M0) UNDIFFERENTIATED NASOPHARYNGEAL CARCINOMA - A POSITIVE EFFECT ON PROGRESSION-FREESURVIVAL, International journal of radiation oncology, biology, physics, 35(3), 1996, pp. 463-469
Authors:
FANDI A
TAAMMA A
AZLI N
BACHOUCHI M
YANES B
CVITKOVIC E
ARMAND J
Citation: A. Fandi et al., 5-FLUOROURACIL (FU) BLEOMYCIN (B), EPIRUBICIN (E), CISPLATIN (P) IN LOCALLY ADVANCED (LA), RECURRENT AND OR IMETASTATIC (REC/MTS) UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE (UNCT) PRELIMINARY ACTIVITY TOXICITY REPORT/, European journal of cancer, 31A, 1995, pp. 401-401
Authors:
FANDI A
YANES B
TAAMMA A
AZLI N
ARMAND JP
DUPUIS O
ESCHWEGE F
SCHWAAB G
CVITKOVIC E
Citation: A. Fandi et al., UNDIFFERENTIATED CARCINOMA OF THE NASOPHA RYNX - EPIDEMIOLOGIC, CLINICAL AND THERAPEUTIC ASPECTS, Bulletin du cancer, 81(7), 1994, pp. 571-586